Success Metrics

Clinical Success Rate

81.3%

Based on 13 completed trials

Completion Rate

81%(13/16)

Active Trials

0(0%)

Results Posted

85%(11 trials)

Terminated

3(19%)

Phase Distribution

Ph phase_2

19%

Ph early_phase_1

Ph not_applicable

13%

Ph phase_3

13%

Ph phase_4

19%

Ph phase_1

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Early Phase 1First-in-human

1(7.7%)

Phase 1Safety & dosage

2(15.4%)

Phase 2Efficacy & side effects

3(23.1%)

Phase 3Large-scale testing

2(15.4%)

Phase 4Post-market surveillance

3(23.1%)

N/ANon-phased studies

2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.3%

13 of 16 finished

Non-Completion Rate

18.8%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(13)

Terminated(3)

Detailed Status

Completed13

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

81.3%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (7.7%)

Phase 12 (15.4%)

Phase 23 (23.1%)

Phase 32 (15.4%)

Phase 43 (23.1%)

N/A2 (15.4%)

Trials by Status

completed1381%

terminated319%

Recent Activity

0 active trials

Showing 5 of 16

completednot_applicable

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

NCT00841100

View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials

NCT02353312Not Applicable

Rhode Island Diastolic Dysfunction - Heart Failure

Completed

NCT06481709Phase 1

Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects

Completed

NCT01965912Phase 4

Kuvan®'s Effect on the Cognition of Children With Phenylketonuria

Completed

NCT00778206

PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry

Completed

NCT00841100Phase 2

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

Completed

NCT02042196Early Phase 1

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

Completed

NCT03864029

Retrospective Observational Safety Effectiveness With Kuvan in hpA

Completed

NCT00943579Phase 2

Open-Label Extension Study of Kuvan for Autism

Completed

NCT01376908Phase 3

Kuvan® in Phenylketonuria Patients Less Than 4 Years Old

Completed

NCT01706965Phase 1

Kuvan in People With Schizophrenia and Schizoaffective Disorder

Completed

NCT01617070Phase 4

Effects of Kuvan on Melatonin Secretion

Completed

NCT01806051Not Applicable

A Pilot Study on Diurnal Variation

Terminated

NCT01395394Phase 2

Phenylketonuria, Oxidative Stress, and BH4

Terminated

NCT01732471Phase 3

Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria

Completed

NCT01082328Phase 4

Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period

Completed

NCT00827762

Behavioral Effects of Kuvan in Children With Mild Phenylketonuria

Terminated

All 16 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 16